Report overview
In cancers, where mutations have led to the loss of function of one gene, using a drug molecule that specifically targets the corresponding gene of the synlet pair has been demonstrated to be a viable and effective therapeutic regimen. Recent advances in biomarker research, including the development of companion diagnostics, in combination with modern molecular screening platforms, which include clustered regularly interspaced short palindromic repeats (CRISPR)- and RNA interference (RNAi)-based screening techniques, have led to the identification of a number of synthetically lethal gene pairs.
This report contains market size and forecasts of Synthetic Lethality-based Drugs and Targets in Global, including the following market information:
Global Synthetic Lethality-based Drugs and Targets Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Synthetic Lethality-based Drugs and Targets market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Monotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Synthetic Lethality-based Drugs and Targets include AbbVie, AstraZeneca, BeiGene, Clovis Oncology, GlaxoSmithKline, Pfizer, AtlasMedx, Chordia Therapeutics and IDEAYA Biosciences, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Synthetic Lethality-based Drugs and Targets companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Synthetic Lethality-based Drugs and Targets Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Synthetic Lethality-based Drugs and Targets Market Segment Percentages, by Type, 2021 (%)
Monotherapy
Combination Therapy
Global Synthetic Lethality-based Drugs and Targets Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Synthetic Lethality-based Drugs and Targets Market Segment Percentages, by Application, 2021 (%)
Medical Research Institution
Hospital and Clinic
Other
Global Synthetic Lethality-based Drugs and Targets Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Synthetic Lethality-based Drugs and Targets Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Synthetic Lethality-based Drugs and Targets revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Synthetic Lethality-based Drugs and Targets revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie
AstraZeneca
BeiGene
Clovis Oncology
GlaxoSmithKline
Pfizer
AtlasMedx
Chordia Therapeutics
IDEAYA Biosciences
Mission Therapeutics
Repare Therapeutics
Sierra Oncology
SyntheX Labs
